视网膜血管化速率预测早产儿视网膜病变且不受低剂量贝伐珠单抗治疗影响
这项回顾性连续队列研究纳入英国牛津一家三级新生儿病房76例早产儿共132只眼,利用超广角成像筛查测量视网膜血管化速率。血管化较慢与早产儿视网膜病变(ROP)严重程度增加相关,C组眼时间血管化速率(TVR)较AB组慢29%(P=0.04)。基于TVR、胎龄和出生体重的机器学习模型在保留队列32只眼中正确预测30只眼(平衡准确率95.8%)。超低剂量(0.16 mg)贝伐珠单抗治疗前后TVR无显著变化。
要点
- 基于超广角成像的ROP筛查可量化视网膜血管化速率,TVR较慢与ROP严重程度增加相关。
- 基于TVR、胎龄和出生体重的机器学习模型在保留队列中平衡准确率达95.8%。
- 超低剂量(0.16 mg)贝伐珠单抗治疗前后TVR无显著变化。
核心结论
- 基于超广角成像的ROP筛查能够量化视网膜血管化速率,可独立于出生体重和胎龄对1型ROP提供早期预测。
- 生理性视网膜血管化速率似乎不受超低剂量抗血管内皮生长因子(anti-VEGF)治疗的显著影响,这对周边无血管视网膜的发育及高危婴儿抗VEGF干预时机具有重要意义。
研究设计与样本
- 回顾性连续队列研究,纳入英国牛津一家三级新生儿病房76例早产儿共132只眼,平均胎龄26.0(±2.0 SD)周,平均出生体重815(±264)g,接受纵向超广角成像ROP筛查。
- 沿平分血管弓的直线测量「视盘至颞侧血管前沿」与「视盘至黄斑中心凹」距离之比,取≥3个时间点对月经后年龄作图计算每只眼的时间血管化速率(TVR)。
- 以TVR、胎龄和出生体重为预测因子构建机器学习模型,将眼分为AB组(无ROP和2型ROP)或C组(1型ROP),并在32只眼(19例婴儿,其中8只眼、5例婴儿需治疗)的保留队列中验证。
- 比较37只眼(20例婴儿)接受超低剂量(0.16 mg)玻璃体腔注射贝伐珠单抗治疗前后的TVR。
主要发现
- 视网膜血管化较慢与ROP严重程度增加相关,C组眼(n=50)TVR较AB组眼(n=33无ROP和n=49 2型ROP)慢29%(P=0.04)。
- 模型正确预测32只眼中的30只眼ROP结局,平衡准确率为95.8%。
- 贝伐珠单抗治疗前后TVR无显著变化,平均治疗后影像随访7.7(±7.9)周(右眼P=0.60,左眼P=0.71)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the rate of retinal vascularization derived from ultra-widefield (UWF) imaging-based retinopathy of prematurity (ROP) screening as predictor of type 1 ROP and characterize the effect of anti-vascular endothelial growth factor (anti-VEGF) therapy on vascularization rate. DESIGN: Retrospective, consecutive cohort study. SUBJECTS: The study included 132 eyes of 76 premature infants with a mean gestational age (GA) of 26.0 (±2.0 SD) weeks and birthweight (BW) of 815 (±264) g, who underwent longitudinal UWF imaging for ROP screening, at a level 3 neonatal unit in Oxford, United Kingdom. METHODS: The extent of retinal vascularization on each UWF image was measured as the ratio between "disc-to-temporal vascular front" and "disc-to-fovea" distance along a straight line bisecting the vascular arcades. Measurements from ≥3 time points plotted against post-menstrual age (PMA) enabled calculation of temporal vascularization rate (TVR) for each eye. Using TVR, GA, and BW as predictors, a machine learning model was created to classify eyes as either group AB (no ROP and type 2 ROP) or group C (type 1 ROP). The model was validated in a withheld cohort of 32 eyes (19 infants), of which 8 eyes (5 infants) required treatment. TVR in 37 eyes (20 infants) was compared before and after ultra-low-dose (0.16 mg) intravitreal bevacizumab treatment. MAIN OUTCOME MEASURES: The rate of retinal vascularization was determined. RESULTS: Slower retinal vascularization correlated with increasing ROP severity, with TVR being 29% slower in group C eyes (n=50) than group AB eyes (n=33 no ROP and n=49 type 2 ROP) (P = .04). Our model correctly predicted ROP outcomes of 30/32 eyes, achieving a balanced accuracy of 95.8%. No significant change in TVR was found before and after bevacizumab treatment with mean posttreatment imaging follow-up of 7.7 (±7.9) weeks (P = .60 right eyes, P = .71 left eyes). CONCLUSIONS: UWF imaging-based ROP screening enables quantification of retinal vascularization rate, which can provide early prediction of type 1 ROP independent of BW and GA. Rate of physiological retinal vascularization does not appear to be significantly affected by ultra-low-dose anti-VEGF treatment, which has significant implications for the development of peripheral avascular retina and timing of anti-VEGF intervention to prevent disease progression in high-risk infants.
引用
- Chang E, Josan A, Purohit R, et al. Retinal Vascularization Rate Predicts Retinopathy of Prematurity and Remains Unaffected by Low-Dose Bevacizumab Treatment. Am J Ophthalmol. 2025. PMID: 40054545. doi:10.1016/j.ajo.2025.02.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。